Page content

Article content

Biotech Stock Idera Pharmaceuticals

Biotech stock Idera Pharmaceuticals (IDRA) announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of tilsotolimod and ipilimumab for the treatment of melanoma prior to the opening of markets on Friday, December 14, 2018.

I’m thinking why would IDRA release a PR about the event if the data was bad?

Further, the company plans to do a slide show and conference call after the data release. Why would the company do a slide show and conference call if the data was bad? There wouldn’t be much to discuss if it was poor IMO. I could be wrong though on both accounts.

Institutional ownership is up 12.25% over the previous 3 month period. I’m thinking institutional traders know better than anyone what they are investing in as they often have greater access to company officers than you or I. Again, circumstantial information at best.

We also have four analysts giving the IDRA stock a buy rating over the last few months.

Swayampakula Ramakanth of H.C. Wainwright gives a buy with an $18 price target. Konstantinos Aprilakis of JMP Securities gives a buy rating with a $32 price target. Gena Wang of Barclays gives a buy with a $14 price target. Finally, Anupam Rama of J.P. Morgan gives a buy with a price target of $15. Again, none of this means the data release on Friday is going to be good but I’m thinking all these smart analysts with greater access to the company than you or I know what they are doing. I COULD BE WRONG THOUGH.

IDRA Stock

I like the setup on IDRA stock. There is reduced volatility while prices have been consolidating. There is a support zone below the current price at $6.08, a stop order could be placed below this zone.

Large players are showing some interest in IDRA over the last couple of days, which is a bullish sign.

If you are a Premium member, you know I took a long position in IDRA ahead of Friday’s pre-market announcement and I will let you know when I sell too.

I am not adding to the long-term portfolios because the catalyst is a short-term Friday data release.

January 21, 2019Lynne Powell just Sold 3,046 shares of BioCryst Pharmaceuticals, Inc. (BCRX), be careful if you are long!; VITA MOBILE SYSTEMS (VMSI) Shorts Increased By 600% The FinExaminerLynne Powell Insider Sell Deal totalling around $28236 U.S Dollars was made public online in a legal report submitt ...

January 20, 2019Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), TransAct Technologies Incorporated (NasdaqGM:TACT) Gross Margin Score in the Spotlight Felton NewsInvestors may be interested in viewing the Gross Margin score on shares of Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA). The name currently has a s ...

January 20, 2019Idera Pharmaceuticals (IDRA) Raised to “Buy” at Zacks Investment Research XNewsPressZacks Investment Research upgraded shares of Idera Pharmaceuticals (NASDAQ:IDRA) from a hold rating to a buy rating in a research note released on ... ...

January 19, 2019Technical Stock Update: 20D Lower Donchian at 2.8 for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Herdon GazetteStock market players may have differing opinions on which type of research approach is best. Individual investors who prefer buy and hold strategies may be ... ...

Topics

Search By Company Name or Ticker

Search for:

Sort by

DISCLAIMER

I am not a licensed advisor or a registered financial consultant. Alerts should not be considered as recommendations or solicitations to buy or sell any security. You assume complete responsibility for your own trades and investments. The market is volatile, and trades and investments can result in total loss of capital. I assume no responsibility for any losses. I may have positions in some stocks that are mentioned and I will disclose that when an article is published. I may liquidate these positions at my discretion without notification. My past results are not necessarily indicative of future performance. Any trades or investments are committed at your own risk. The opinions posted here are intended for educational purpose only, and I am by no means liable for any potential damages that may be incurred from this information.